首页> 外文期刊>Rheumatology international. >Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease.
【24h】

Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease.

机译:比较甲氧苄氨嘧啶-磺胺甲基异恶唑和雾化喷他idine对预防免疫力低下的结缔组织病患者的肺炎支原体肺炎的预防作用。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

To evaluate the efficacy of primary prophylaxis for Pneumocystis jiroveci pneumonia (PCP) in patients with connective tissue disease (CTD) and immunosuppression, we compared trimethoprim-sulfamethoxazole (TMP-SMZ) with aerosolized pentamidine. Forty-eight CTD patients of Kitasato University Hospital whose CD4+ lymphocyte count in the peripheral blood was less than 300 mul(-1) were reviewed from 2002 to 2004. Twenty-seven patients received TMP-SMZ and none of them developed PCP. Among 18 patients receiving aerosolized pentamidine, three patients developed PCP. These data indicate that TMP-SMZ is better for prophylaxis than aerosolized pentamidine.
机译:为了评估对结缔组织病(CTD)和免疫抑制患者的原发性肺炎支原体肺炎(PCP)预防的疗效,我们比较了甲氧苄氨磺胺甲基异恶唑(TMP-SMZ)与雾化喷他idine。 2002年至2004年,对北里大学医院的48例CTD患者外周血CD4 +淋巴细胞计数低于300 mul(-1)进行了回顾。27例患者接受了TMP-SMZ治疗,但均未发生PCP。在18例接受雾化喷他idine的患者中,有3例患上了PCP。这些数据表明,TMP-SMZ的预防效果优于雾化的喷他idine。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号